By

Botox Study Details

Allergan has released details of its Phase II Botox study, the findings of which researchers presented at today’s AHS conference.

Based on these findings, the FDA has approved Allergan to progress to the Phase III study. This study, scheduled to begin late this year, will investigate how safe and effective Botox is for migraine patients with chronic daily headache.

By

AHS’s Annual Meeting Underway

The American Headache Society’s 47th annual scientific meeting began today. Press releases are now available for some of the key conference presentations. There’s some good stuff here!

2/9/10: These press releases are no longer available from AHS.